This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Graybill, J. R.
Right arrow Articles by Luther, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Graybill, J. R.
Right arrow Articles by Luther, M. F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 1998, p. 2371-2374, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Efficacy of Nikkomycin Z in the Treatment of Murine Histoplasmosis

John R. Graybill,1,2,* Laura K. Najvar,2 Rosie Bocanegra,2 Richard F. Hector,3 and Michael F. Luther1

Audie Murphy Memorial Veterans Hospital,1 University of Texas Health Science Center,2 San Antonio, Texas 78284, and Shaman Pharmaceuticals, South San Francisco, California 940803

Received 29 December 1997/Returned for modification 30 January 1998/Accepted 10 June 1998

Immune-competent ICR and BALB/c athymic (nude) mice were infected intravenously with Histoplasma capsulatum and treated with either fluconazole or nikkomycin Z or 5% dextrose (controls). In immune-competent ICR mice, fluconazole and nikkomycin Z both prolonged survival when given at 5 mg/kg of body weight twice daily. When administered in doses as low as 2.5 mg/kg twice daily, nikkomycin Z reduced fungal counts in both the spleen and liver. When both drugs were combined, there was no antagonism, and in combined therapy spleen and liver counts were reduced more than for either drug alone. However, nikkomycin Z had no effect on brain fungal burden. In nude mice fluconazole and nikkomycin Z had an additive effect in prolongation of survival and reduction of liver and spleen burden. Nikkomycin Z is well tolerated, is at least as effective as fluconazole, and may interact beneficially with fluconazole for treatment of murine histoplasmosis.

* Corresponding author. Mailing address: Division of Infectious Diseases (111F), Audie Murphy Memorial Veterans Hospital, 7400 Merton Minter Blvd., San Antonio, TX 78284.

Antimicrobial Agents and Chemotherapy, September 1998, p. 2371-2374, Vol. 42, No. 9
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Nix, D. E., Swezey, R. R., Hector, R., Galgiani, J. N. (2009). Pharmacokinetics of Nikkomycin Z after Single Rising Oral Doses. Antimicrob. Agents Chemother. 53: 2517-2521 [Abstract] [Full Text]  
  • Cuenca-Estrella, M. (2004). Combinations of antifungal agents in therapy-what value are they?. J Antimicrob Chemother 54: 854-869 [Abstract] [Full Text]  
  • Clemons, K. V., Martinez, M., Calderon, L., Stevens, D. A. (2002). Efficacy of Ravuconazole in Treatment of Systemic Murine Histoplasmosis. Antimicrob. Agents Chemother. 46: 922-924 [Abstract] [Full Text]  
  • Bigliardi, E., Bernuzzi, A. M., Corona, S., Gatti, S., Scaglia, M., Sacchi, L. (2000). In Vitro Efficacy of Nikkomycin Z against the Human Isolate of the Microsporidian Species Encephalitozoon hellem. Antimicrob. Agents Chemother. 44: 3012-3016 [Abstract] [Full Text]  
  • Goldberg, J., Connolly, P., Schnizlein-Bick, C., Durkin, M., Kohler, S., Smedema, M., Brizendine, E., Hector, R., Wheat, J. (2000). Comparison of Nikkomycin Z with Amphotericin B and Itraconazole for Treatment of Histoplasmosis in a Murine Model. Antimicrob. Agents Chemother. 44: 1624-1629 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Andriole, V. T. (1999). Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother 44: 151-162 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»